The effect of the incretin hormones GLP-1 and GIP to promote pancreatic β-cell function is exploited by an expansive menu of incretin mimetics for the treatment of type 2 diabetes (T2D); however, the incretin effect is well known to diminish as T2D progresses. This evidence concerns the gene GCG and type 2 diabetes mellitus.